# Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations

> **NCT04790409** · PHASE2 · COMPLETED · sponsor: **Zhejiang Cancer Hospital** · enrollment: 21 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** sintilimab and anlotinib

## Key facts

- **NCT ID:** NCT04790409
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-01
- **Primary completion:** 2023-09-13
- **Final completion:** 2023-09-13
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2023-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04790409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04790409, "Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04790409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*